IMA Advisory Services Inc. Cuts Position in Repligen Corporation $RGEN

IMA Advisory Services Inc. trimmed its position in shares of Repligen Corporation (NASDAQ:RGEN) by 90.4% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 730 shares of the biotechnology company’s stock after selling 6,862 shares during the period. IMA Advisory Services Inc.’s holdings in Repligen were worth $98,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the company. Hantz Financial Services Inc. lifted its stake in Repligen by 2,663.6% during the 2nd quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 293 shares in the last quarter. CWM LLC lifted its position in shares of Repligen by 67.2% during the third quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 135 shares in the last quarter. Center for Financial Planning Inc. boosted its stake in shares of Repligen by 34.2% in the second quarter. Center for Financial Planning Inc. now owns 494 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 126 shares during the period. Trust Co. of Vermont acquired a new position in shares of Repligen in the third quarter valued at approximately $67,000. Finally, Wilmington Savings Fund Society FSB increased its stake in Repligen by 2,750.0% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 513 shares of the biotechnology company’s stock worth $69,000 after buying an additional 495 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Trading Up 2.9%

RGEN opened at $136.44 on Friday. The business’s 50-day simple moving average is $159.23 and its 200-day simple moving average is $145.53. The company has a market cap of $7.68 billion, a P/E ratio of 6,825.41, a PEG ratio of 2.42 and a beta of 1.13. Repligen Corporation has a one year low of $102.96 and a one year high of $175.77. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.14 and a current ratio of 8.36.

Insiders Place Their Bets

In other Repligen news, COO James Bylund sold 2,191 shares of the firm’s stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $151.21, for a total transaction of $331,301.11. Following the transaction, the chief operating officer owned 21,520 shares of the company’s stock, valued at approximately $3,254,039.20. This trade represents a 9.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Karen A. Dawes sold 275 shares of Repligen stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $161.00, for a total value of $44,275.00. Following the sale, the director owned 91,821 shares in the company, valued at $14,783,181. This trade represents a 0.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 4,657 shares of company stock worth $706,877 over the last ninety days. Insiders own 1.20% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on RGEN. Weiss Ratings cut shares of Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, January 30th. Wall Street Zen upgraded Repligen from a “hold” rating to a “buy” rating in a report on Saturday, February 7th. Wells Fargo & Company upped their price target on Repligen from $175.00 to $190.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Barclays increased their price target on Repligen from $175.00 to $200.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Finally, Jefferies Financial Group set a $160.00 price objective on Repligen and gave the stock a “hold” rating in a research report on Tuesday, October 28th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Repligen presently has an average rating of “Moderate Buy” and a consensus target price of $177.92.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.